ban on compounded semaglutide FDA Warns Certain Forms of Safety put first in compounding

Medicare news headlines often sound broader than the current benefit reality

Yes, 2.5 mg of Retatrutide is expected to activate the glucagon receptor because Retatrutide is designed as a triple agonist that targets GLP-1, GIP, and glucagon receptors simultaneously

Retatrutide has developed one of the most rapidly growing pre-clinical research profiles of any metabolic peptide currently in active study: Pre-clinical metabolic research in obese animal models has reported body weight and fat mass reductions with Retatrutide that exceed those observed with dual-receptor compounds including Tirzepatide at comparable doses and suggesting that the addition of glucagon receptor engagement to combined GLP-1/GIP agonism produces meaningfully greater metabolic effects in experimental settings

Novo Nordisk has already submitted an application to the FDA for its high-dose (25 mg) oral semaglutide pill for weight management

Retatrutide is commonly referred to online as a peptide, and it is an investigational molecule studied in clinical trials under the development code LY3437943

Accessed November 8, 2023